Enzon Pharmaceuticals (ENZN) 10-K 21 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 02, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	ENZON PHARMACEUTICALS, INC.
Entity Central Index Key	727,510
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 9,727,213
Trading Symbol	ENZN
Entity Common Stock, Shares Outstanding		44,214,603

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 7,478	$ 7,639
Other current assets	94	270
Total current assets	7,572	7,909
Refundable tax credits receivable	1,940	0
Deferred tax assets	0	3,362
Total assets	9,512	11,271
Current liabilities:
Accounts payable	225	770
Accrued expenses and other current liabilities	143	170
Total current liabilities	368	940
Commitments and contingencies
Stockholders’ equity:
Preferred stock - $0.01 par value, authorized 3,000,000 shares; no shares issued and outstanding at December 31, 2017 and 2016	0	0
Common stock - $0.01 par value, authorized 170,000,000 shares; issued and outstanding 44,214,603 shares at December 31, 2017 and 2016	442	442
Additional paid-in capital	83,649	90,281
Accumulated deficit	(74,947)	(80,392)
Total stockholders’ equity	9,144	10,331
Total liabilities and stockholders’ equity	$ 9,512	$ 11,271

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	44,214,603	44,214,603
Common stock, shares outstanding	44,214,603	44,214,603

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues:
Royalties	$ 8,379	$ 8,314
Miscellaneous income	0	63
Total revenues	8,379	8,377
Operating expenses:
General and administrative	1,371	1,679
Lease termination costs	0	54
Total operating expenses	1,371	1,733
Other income (expense):
Income before income tax expense	7,008	6,644
Income tax expense	1,563	7,770
Net income (loss)	$ 5,445	$ (1,126)
Income (loss) per common share
Basic (in dollars per share)	$ 0.12	$ (0.03)
Diluted (in dollars per share)	$ 0.12	$ (0.03)
Weighted average number of shares
Basic	44,215	44,215
Diluted	44,215	44,215

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2015	$ 18,089	$ 442	$ 96,913	$ (79,266)
Balance (in shares) at Dec. 31, 2015		44,215
Net loss	(1,126)	$ 0	0	(1,126)
Common stock dividend	(6,632)	0	(6,632)	0
Balance at Dec. 31, 2016	10,331	$ 442	90,281	(80,392)
Balance (in shares) at Dec. 31, 2016		44,215
Net loss	5,445	$ 0	0	5,445
Common stock dividend	(6,632)	0	(6,632)	0
Balance at Dec. 31, 2017	$ 9,144	$ 442	$ 83,649	$ (74,947)
Balance (in shares) at Dec. 31, 2017		44,215

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ 5,445	$ (1,126)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred tax provision	3,362	7,749
Changes in operating assets and liabilities:
(Decrease) increase in other current assets	176	(163)
Increase in refundable tax credit receivable	(1,940)	0
Decrease in accrued lease termination costs	0	(4,506)
Increase (decrease) in accounts payable	(545)	680
Decrease in accrued expenses and other current liabilities	(27)	(35)
Net cash provided by operating activities	6,471	2,599
Cash flows from financing activities:
Common stock dividends	(6,632)	(6,632)
Net cash used in financing activities	(6,632)	(6,632)
Net decrease in cash	(161)	(4,033)
Cash at beginning of year	7,639	11,672
Cash at end of year	7,478	7,639
Supplemental cash flows disclosure:
Cash paid for income taxes	$ 0	$ 135,000

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	(1) Description of Business Enzon Pharmaceuticals, Inc. (together with its subsidiaries, “Enzon” or the “Company,” “we” or “us”), manages its sources of royalty revenues from existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize Enzon’s proprietary technology. In 2017, the primary source of the Company’s royalty revenues was the revenues from Nektar Therapeutics, Inc. (“Nektar”) pursuant to the Nektar, which generated non-recurring royalty revenues of $7 million (see below). The receipt of this $7 million satisfied Prior to 2017, the primary source of the Company’s royalty revenues was derived from sales of PegIntron, which is marketed by Merck &; Co., Inc. (“Merck”). Prior to 2013, the Company was dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs. The Company currently has no clinical operations and limited corporate operations. The Company 7 64 877,000 In April 2013, the Company announced that it intended to distribute excess cash, expected to arise from ongoing royalty revenues, in the form of periodic dividends to stockholders. On February 4, 2016, the Company’s Board adopted a Plan of Liquidation and Dissolution (the “Plan of Liquidation and Dissolution”), the implementation of which has been postponed. (See Note 15 Other Corporate Events.) Under the Company’s existing agreements with certain third party licensees, the Company may be entitled to (i) potential future milestone payments contingent upon the achievement of certain milestones with respect to several other drug products in various stages of clinical and preclinical development and (ii) potential future royalty payments related to any future sales of these drug products. Due to the challenges associated with developing and obtaining approval for drug products, there is substantial uncertainty whether any of these milestones will be achieved. The Company also has no control over the time, resources and effort that these third party licensees may devote to their programs and limited access to information regarding or resulting from such programs. Accordingly, there can be no assurance that the Company will receive any of the milestone or royalty payments under these agreements. The Company may be entitled to certain potential future milestone payments contingent upon the achievement of certain regulatory approval-related milestones with respect to Oncaspar from Shire plc (“Shire”), which assumed the milestone payment obligations when it acquired the Oncaspar product portfolio from Sigma-Tau Finanziaria S.p.A. in July 2015. In an investor presentation, Shire stated that it anticipated filing a Biologics License Application (“BLA”) for SC Oncaspar with the FDA in the fourth quarter of 2017. In February 2018, Shire indicated that it was in the registration stage and awaiting further regulatory action. 7.0 any of the Company’s other third party licensees On June 26, 2017, the Company entered into the Nektar Second Amendment, wherein Nektar agreed to buy-out all remaining payment obligations to the Company under the Nektar License Agreement. In consideration for fully paid-up licenses under the Nektar License Agreement and for the dismissal with prejudice of all claims and counterclaims asserted in the litigation with Nektar, Nektar agreed to pay the Company the sum of $ 7.0 3.5 3.5 7.0 3.5 3.5 In March 2017, Merck notified the Company that it had overpaid it approximately $ 770,000 25 564,000 150,000 150,000 213 111,000 313,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	(2) Summary of Significant Accounting Policies The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include legal and contractual contingencies and income taxes. Although management bases its estimates on historical experience, relevant current information and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. The carrying values of cash, other receivable, other current assets, accounts payable, accrued expenses and other current liabilities in the Company’s consolidated balance sheets approximated their fair values at December 31, 2017 and 2016 due to their short-term nature. As of December 31, 2017, the Company held no cash equivalents or marketable securities. Royalty revenues from the Company’s agreements with third parties are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee, which is typically during the quarter following the quarter in which the sales occurred. The Company does not participate in the selling or marketing of products for which it receives royalties. No provision for uncollectible accounts is established upon recognition of revenues. Contingent payments due under the asset purchase agreement for the sale of the Company’s former specialty pharmaceutical business are recognized as income when the milestone has been achieved and collection is assured. Such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense. The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned. The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at date of grant or modification and vesting, including the likelihood of achieving performance goals. Furthermore, the application of the Black-Scholes valuation model employs weighted average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk free interest rate, and dividends, if any, to determine fair value. Expected volatility is based on historical volatility of the Company’s common stock; the expected term until exercise represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.

Recently Adopted Accounting Pro

Recently Adopted Accounting Pronouncements	12 Months Ended
	Dec. 31, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	(3) Recently Adopted Accounting Pronouncements In January 2017, the 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business that clarifies the definition of a business and determines when an integrated set of assets and activities is not a business. This framework requires that if substantially all of the fair value of gross assets acquired or disposed of is concentrated in a single asset or group of similar identifiable assets, the assets would not represent a business. The standard is effective for interim and annual periods beginning after December 15, 2017 with early adoption permitted. The Company does not believe the adoption of the amendments in this ASU will have a material effect on our consolidated financial position and results of operations. In May 2014, the FASB issued ASU The Company has assessed the impact of this update and has concluded that its adoption will not have a material impact on the Company’s consolidated financial statements. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its consolidated financial statements.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	(4) Accounts Payable and Accrued Expenses In March 2017, Merck notified the Company that it had overpaid it approximately $ 770,000 25 770,000 In the second quarter of 2017, Merck notified the Company that they discovered additional overpayments to the Company resulting from their inaccuracy as to the date on which the Company’s right to receive royalties from various countries’ sales of PegIntron expired. Such net overpayment to the Company aggregated approximately $ 564,000 150,000 111,000 1.3 313,000 1.6 225,000 December 31, December 31, 2017 2016 Professional and consulting fees $ 142 $ 140 Other 1 30 $ 143 $ 170

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	(5) Stockholders’ Equity Preferred Stock The Company has authorized 3,000,000 100,000 Common Stock As of December 31, 2017, the Company reserved 7,097,697 Section 382 Rights Agreement On April 30, 2014, the Company’s Board of Directors adopted a Section 382 rights plan and declared a dividend distribution of one right for each outstanding share of the Company’s common stock to stockholders of record at the close of business on May 14, 2014. Such rights lapsed, unexercised, at the stated expiration date of April 30, 2017 and have not been replaced.

Miscellaneous Income

Miscellaneous Income	12 Months Ended
	Dec. 31, 2017
Miscellaneous Income [Abstract]
Miscellaneous Income [Text Block]	(6) Miscellaneous Income Included in miscellaneous income in 2016 was approximately $ 42,000 There was no comparable amount in 2017.

Cash Dividend

Cash Dividend	12 Months Ended
	Dec. 31, 2017
Dividends, Cash [Abstract]
Cash Dividend [Text Block]	(7) Cash Dividend On November 14, 2016, the Board declared a special cash dividend of $ 0.15 6.6 On August 10, 2017, the Company’s Board of Directors declared a special cash dividend of $ 0.15 6.6

Income (Loss) Per Common Share

Income (Loss) Per Common Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	(8) Income (Loss) Per Common Share Basic income (loss) per common share is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding during the period. Restricted stock awards and restricted stock units (collectively, nonvested shares) are not considered to be outstanding shares until the service or performance vesting period has been completed. The diluted income (loss) per share calculation would normally involve adjusting the denominator as described here if the effect is dilutive. The denominator would include both the weighted average number of shares of common stock outstanding and common stock equivalents. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method and shares issuable under the employee stock purchase plan (ESPP). For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and nonvested shares using the treasury stock method and shares issuable under the employee stock purchase plan (ESPP). During 2017 and 2016, there were no common stock equivalents. 2017 2016 Income (Loss) per Common Share - Basic Net income (loss) for year $ 5,445 $ (1,126) Weighted-average number of common shares outstanding 44,215 44,215 Basic income (loss) per share $ 0.12 $ (0.03) Income (Loss) per Common Share - Diluted Net income (loss) for year $ 5,445 $ (1,126) Weighted-average number of common shares outstanding 44,215 44,215 Weighted-average incremental shares related to assumed exercise of stock options, vesting of nonvested shares, and ESPP - - Weighted-average common shares outstanding and common share equivalents 44,215 44,215 Diluted income (loss) per share $ 0.12 $ (0.03)

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2017
Stock Options [Abstract]
Stock Options Disclosure [Text Block]	(9) Stock Options Through the Compensation Committee of the Company’s Board of Directors, the Company administers the 2011 Stock Option and Incentive Plan, which provides incentive and non-qualified stock option benefits for employees, officers, directors and independent contractors providing services to Enzon and its subsidiaries. Options granted to employees generally vest over four years from date of grant and options granted to directors vest after one year. The exercise price of the options granted must be at least 100 percent of the fair value of the Company’s common stock at the time the options are granted. Options may be exercised for a period of up to ten years from the grant date. As of December 31, 2017, the 2011 plan authorized equity-based awards for 5 4.4 2013 Outside Director Compensation Plan In connection with the special cash dividend that was paid on September 26, 2017 to stockholders of record as of August 30, 2017 (see Note 7), the Compensation Committee of the Board approved equitable adjustments to the Company’s outstanding stock options and restricted stock units. In connection with the special cash dividend declared and paid in 2016 (see Note 7), the Compensation Committee of the Board approved equitable adjustments to the Company’s outstanding stock options and restricted stock units. Weighted Weighted Average Average Exercise Remaining Aggregate Price Per Contractual Intrinsic Options Option Term (years) Value ($000) Outstanding at January 1, 2017 219 $ 2.66 2.60 $ - Granted at exercise prices which equaled the fair value on the date of grant - - - - Exercised - - - - Expired and forfeited (177) - - - Outstanding at December 31, 2017 42 $ 3.11 3.23 $ - Vested and expected to vest at December 31, 2017 42 $ 3.11 3.23 $ - Exercisable at December 31, 2017 42 $ 3.11 3.23 $ - As of December 31, 2017, there was no unrecognized compensation cost related to unvested options that the Company expects to recognize. No options were granted during the years ended December 31, 2017 and 2016. In the years ended December 31, 2017 and 2016, the Company recorded no stock-based compensation related to stock options. The Company’s policy is to use newly issued shares to satisfy the exercise of stock options. The Company received no cash from exercises of stock options in either of the years ended December 31, 2017 and 2016.

Restricted Stock Awards and Res

Restricted Stock Awards and Restricted Stock Units (Nonvested Shares)	12 Months Ended
	Dec. 31, 2017
Restricted Stock Awards And Restricted Stock Units [Abstract]
Restricted Stock Awards And Restricted Stock Units Nonvested Shares [Text Block]	(10) Restricted Stock Awards and Restricted Stock Units (Nonvested Shares) The 2011 Stock Option and Incentive Plan and, prior to that, the 2001 Incentive Stock Plan provide for the issuance of restricted stock awards and restricted stock units (collectively, nonvested shares) to employees, officers and directors. However, there will be no further grants made pursuant to those plans and, as of December 31, 2017, there were no nonvested shares outstanding.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	(11) Income Taxes Year Ended December 31, 2017 2016 Current: Federal $ (1,801) $ 19 State and foreign 2 2 Total current (1,799) 21 Deferred: Federal and state 3,362 7,749 Income tax provision $ 1,563 $ 7,770 Year Ended December 31, 2017 2016 Income tax provision at federal statutory rate $ 2,453 $ 2,325 Add (deduct) effect of: State income taxes, net of federal tax 970 621 Refundable AMT credit (1,801) - Effect of tax rate change as a result of 2017 Tax Cuts and Jobs Act 16,869 - Expiration of state tax credits - 3,303 Expiration of stock options - 2,144 Permanent difference - 57 Change in valuation allowance (14,549) (680) Recognition of windfall NOLs (2,379) - Income tax provision $ 1,563 $ 7,770 No federal income tax expense was incurred in relation to normal operating results due to the utilization of deferred tax assets. December 31, December 31, 2017 2016 Deferred tax assets: Federal and state net operating loss carryforward $ 24,399 $ 40,359 Research and development credits carryforward 16,608 16,608 Capital loss carryforwards 332 482 Federal alternative minimum tax credits - 1,801 Total gross deferred tax assets 41,339 59,250 Less valuation allowance (41,339) (55,888) Net deferred tax assets $ - $ 3,362 On December 22, 2017, the Tax Cuts and Jobs Act (the “Act”) was signed into law. Among its numerous changes to the Internal Revenue Code, the Act reduces the U.S. federal corporate tax rate from 35 21 16.9 In addition, the Act repeals the corporate alternative minimum tax (“AMT”) for years beginning after December 31, 2017 and allows companies with existing alternative minimum tax credit (“MTC”) carryforwards as of December 31, 2017 to receive refunds of the credits in tax years after 2017 and before 2022 in an amount equal to 50% (100% in 2021) of the excess MTC over the amount of the credit allowable for the year against regular tax liability. As of December 31, 2016, the Company had approximately $ 1.8 140,000 1.9 A valuation allowance is provided when it is more likely than not that some portion of all of the deferred tax assets will not be realized. Because the Company has projected little or no taxable income for the years 2018 through 2021, it is more likely than not that the deferred tax assets will not be realized. At December 31, 2017, the Company had federal net operating loss carryforwards of approximately $106 million that expire in the years 2022 through 2031 and New Jersey state net operating loss carryforwards of approximately $29 million that expire in the years 2030 through 2031. The Company also has federal capital loss carryforwards of approximately $1.2 million that expire in 2018 and federal research and development tax credit carryforwards of approximately $16.6 million for tax reporting purposes that expire in the years 2018 through 2020. The Company’s ability to use the net operating loss and research and development tax credit carryforwards is subject to certain limitations due to ownership changes, as defined by rules pursuant to Section 382 of the Internal Revenue Code of 1986, as amended.

Significant Agreements

Significant Agreements	12 Months Ended
	Dec. 31, 2017
Significant Agreements [Abstract]
Significant Agreements Disclosure [Text Block]	(12) Significant Agreements Merck Agreement As a result of a November 1990 agreement, the Company’s PEGylation technology was used to develop an improved version of the product INTRON A, PegIntron. Merck is responsible for marketing and manufacturing PegIntron on an exclusive worldwide basis and the Company receives royalties on worldwide sales of PegIntron for all indications. The Company has no involvement in the selling or marketing of PegIntron. Merck’s obligation to pay the Company royalties on sales of PegIntron terminates, on a country-by-country basis, upon the later of the date on which the last patent to contain a claim covering PegIntron expires in the country or 15 years after the first commercial sale of PegIntron in such country. The expiration occurred in 2016 in the U.S., and expirations are expected to occur in 2018 in Europe and 2021 in Japan. The royalty percentage to which the Company is entitled will be lower in any country where a PEGylated alpha-interferon product is being marketed by a third party in competition with PegIntron where such third party is not Hoffmann-La Roche. Either party may terminate the agreement upon a material breach of the agreement by the other party that is not cured within 60 days of written notice from the non-breaching party or upon declaration of bankruptcy by the other party. During the quarter ended September 30, 2007, the Company sold a 25 -percent interest in future royalties payable to it by Merck on net sales of PegIntron occurring after June 30, 2007. Nektar Agreement See Note 1 regarding the Nektar Second Amendment, wherein Nektar agreed to buy-out all remaining payment obligations to the Company under the Nektar License Agreement.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	(13) Commitments and Contingent Liabilities The Company has been involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or liquidity.

Leases

Leases	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	(14) Leases The Company’s former premises located at 20 Kingsbridge Road, Piscataway, New Jersey (the “Premises”) were leased by the Company pursuant to an agreement of lease dated as of April 1, 1995, as amended (The “Prime Lease”). On November 13, 2013, the Company and Axcellerate Pharma, LLC (“Axcellerate”) entered into an amendment and restatement of the previously announced Agreement of Sublease, dated as of September 26, 2013, between the Company and Axcellerate. The term of the sublease commenced on November 14, 2013 July 30, 2021 On February 4, 2016, the Company entered into (i) an agreement with the prime landlord and Axcellerate and (ii) a letter agreement with the landlord (the “Letter Agreement”). The Surrender and Release Agreement and the Letter Agreement were intended to supersede the previously disclosed Assignment, Assumption and Release Agreement, dated as of September 11, 2015, between the Company and the prime landlord. Pursuant to the Surrender and Release Agreement, (i) the Company’s Prime Lease, terminated effective as of February 4, 2016 (the “Termination Date”) and (ii) the Company’s Sublease became a direct lease between the prime landlord and Axcellerate effective as of the Termination Date. Pursuant to the Letter Agreement, from and after the Termination Date, the prime landlord has agreed to perform all of the Company’s obligations under the sublease, the prime landlord has waived all claims against the Company in connection with the Prime Lease, the sublease or the Premises and the prime landlord has released the Company from all liability in connection with the Prime Lease and the sublease and, in exchange therefor, on the Termination Date, the Company paid $ 4.25 204,000 52,000 4,506,000 New Principal Executive Offices and Office Service Agreement with Regus Commencing on March 1, 2016, the Company changed the location of its principal executive offices to 20 Commerce Drive, Suite 135, Cranford, New Jersey, 07016. The Company has entered into an office service agreement with Regus Management Group, LLC (“Regus”) for use of office space at this location effective March 1, 2016. The initial term of the agreement was until February 28, 2017. Under the agreement, in exchange for the Company’s right to use the office space at this location, the Company was required to pay Regus an initial service retainer of $ 2,418 1,209 1,259

Other Corporate Events

Other Corporate Events	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Corporate Events [Text Block]	Other Corporate Events On February 4, 2016, the Company’s Board of Directors adopted a Plan of Liquidation and Dissolution (the “Plan of Liquidation and Dissolution”), pursuant to which the Company would, subject to obtaining requisite stockholder approval, be liquidated and dissolved in accordance with Sections 280 and 281(a) of the General Corporation Law of the State of Delaware. In approving the Plan of Liquidation and Dissolution, the Company’s Board of Directors had considered, among other factors, the ability of the Company to obtain no-action relief from the SEC to suspend certain of the Company’s reporting obligations under the Securities Exchange Act of 1934, as amended, and the anticipated cost savings if such relief is granted by the SEC. After further consideration, the Company’s Board of Directors determined that it would be fair, advisable and in the best interests of the Company and its stockholders to postpone seeking stockholder approval of the Plan of Liquidation and Dissolution until a later time to be determined by the Company’s Board of Directors. If dissolution and liquidation of the Company pursuant to the Plan of Liquidation and Dissolution are approved by the Company’s stockholders and implemented by management, it is expected that the Company’s corporate existence will continue for the purpose of winding up its business and affairs through the year 2021, consistent with the expiration of the Company’s existing license arrangements that generate its royalty revenues. The Company has forecasted minimal or no royalty revenues for the years 2018 through 2021. This forecast is based upon a variety of estimates and numerous assumptions made by the Company’s management with respect to, among other matters, forecasted sales of the drug products for which the Company has the right to receive royalties, potential returns and rebates and other matters, many of which are difficult to predict, are subject to significant uncertainties, and are beyond the Company’s control. As a result, there can be no assurance that the estimates and assumptions upon which this forecast is based will prove accurate, that the projected results will be realized or that actual results will not be substantially higher or lower than forecasted. On April 30, 2014, the Company’s Board of Directors adopted a Section 382 rights plan and declared a dividend distribution of one right for each outstanding share of the Company’s common stock to stockholders of record at the close of business on May 14, 2014. The Section 382 Rights Agreement expired by its terms on April 30, 2017 and has not been replaced. On March 18, 2016, George W. Hebard III tendered his resignation as Interim Principal Executive Officer, Interim Chief Operating Officer and Secretary of the Company effective March 31, 2016. On March 18, 2016, the Board of Directors of the Company appointed Andrew Rackear as Chief Executive Officer and Secretary of the Company effective March 31, 2016. The Company’s common stock was delisted from Nasdaq on May 20, 2016 because the Company no longer met the requirement to maintain a minimum bid price of $ 1.00

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include legal and contractual contingencies and income taxes. Although management bases its estimates on historical experience, relevant current information and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments and Fair Value The carrying values of cash, other receivable, other current assets, accounts payable, accrued expenses and other current liabilities in the Company’s consolidated balance sheets approximated their fair values at December 31, 2017 and 2016 due to their short-term nature. As of December 31, 2017, the Company held no cash equivalents or marketable securities.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Royalty revenues from the Company’s agreements with third parties are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee, which is typically during the quarter following the quarter in which the sales occurred. The Company does not participate in the selling or marketing of products for which it receives royalties. No provision for uncollectible accounts is established upon recognition of revenues. Contingent payments due under the asset purchase agreement for the sale of the Company’s former specialty pharmaceutical business are recognized as income when the milestone has been achieved and collection is assured. Such payments are non-refundable and no further effort is required on the part of the Company or the other party to complete the earning process.
Income Tax, Policy [Policy Text Block]	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be realized. The effect of a change in tax rates or laws on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date of the rate change. A valuation allowance is established to reduce the deferred tax assets to the amounts that are more likely than not to be realized from operations. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions. Interest and penalties, if any, related to unrecognized tax benefits, would be recognized as income tax expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Plans The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned. The impact that share-based payment awards will have on the Company’s results of operations is a function of the number of shares awarded, the trading price of the Company’s stock at date of grant or modification and vesting, including the likelihood of achieving performance goals. Furthermore, the application of the Black-Scholes valuation model employs weighted average assumptions for expected volatility of the Company’s stock, expected term until exercise of the options, the risk free interest rate, and dividends, if any, to determine fair value. Expected volatility is based on historical volatility of the Company’s common stock; the expected term until exercise represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option.

Accounts Payable and Accrued 23

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities consist of the following as of December 31, 2017 and 2016 (in thousands): December 31, December 31, 2017 2016 Professional and consulting fees $ 142 $ 140 Other 1 30 $ 143 $ 170

Income (Loss) Per Common Share

Income (Loss) Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Income (loss) per common share information is as follows (in thousands, except per share amounts) for the years ended December 31, 2017 and 2016: 2017 2016 Income (Loss) per Common Share - Basic Net income (loss) for year $ 5,445 $ (1,126) Weighted-average number of common shares outstanding 44,215 44,215 Basic income (loss) per share $ 0.12 $ (0.03) Income (Loss) per Common Share - Diluted Net income (loss) for year $ 5,445 $ (1,126) Weighted-average number of common shares outstanding 44,215 44,215 Weighted-average incremental shares related to assumed exercise of stock options, vesting of nonvested shares, and ESPP - - Weighted-average common shares outstanding and common share equivalents 44,215 44,215 Diluted income (loss) per share $ 0.12 $ (0.03)

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2017
Stock Options [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of the activity in the Company’s outstanding Stock Option Plans, which include the 2011 Stock Option and Incentive Plan, the 2001 Incentive Stock Plan, and the 1987 Non-Qualified Stock Option Plan (options in thousands): Weighted Weighted Average Average Exercise Remaining Aggregate Price Per Contractual Intrinsic Options Option Term (years) Value ($000) Outstanding at January 1, 2017 219 $ 2.66 2.60 $ - Granted at exercise prices which equaled the fair value on the date of grant - - - - Exercised - - - - Expired and forfeited (177) - - - Outstanding at December 31, 2017 42 $ 3.11 3.23 $ - Vested and expected to vest at December 31, 2017 42 $ 3.11 3.23 $ - Exercisable at December 31, 2017 42 $ 3.11 3.23 $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The components of the income tax provision are summarized as follows (in thousands): Year Ended December 31, 2017 2016 Current: Federal $ (1,801) $ 19 State and foreign 2 2 Total current (1,799) 21 Deferred: Federal and state 3,362 7,749 Income tax provision $ 1,563 $ 7,770
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The following table represents the reconciliation between the reported income taxes and the income taxes that would be computed by applying the federal statutory rate (35%) to income before taxes (in thousands): Year Ended December 31, 2017 2016 Income tax provision at federal statutory rate $ 2,453 $ 2,325 Add (deduct) effect of: State income taxes, net of federal tax 970 621 Refundable AMT credit (1,801) - Effect of tax rate change as a result of 2017 Tax Cuts and Jobs Act 16,869 - Expiration of state tax credits - 3,303 Expiration of stock options - 2,144 Permanent difference - 57 Change in valuation allowance (14,549) (680) Recognition of windfall NOLs (2,379) - Income tax provision $ 1,563 $ 7,770
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2017 and 2016, the tax effects of temporary differences that give rise to the deferred tax assets are as follows (in thousands): December 31, December 31, 2017 2016 Deferred tax assets: Federal and state net operating loss carryforward $ 24,399 $ 40,359 Research and development credits carryforward 16,608 16,608 Capital loss carryforwards 332 482 Federal alternative minimum tax credits - 1,801 Total gross deferred tax assets 41,339 59,250 Less valuation allowance (41,339) (55,888) Net deferred tax assets $ - $ 3,362

Description of Business (Detail

Description of Business (Details Textual) - USD ($)	1 Months Ended			3 Months Ended			12 Months Ended
	Mar. 31, 2018	Jun. 26, 2017	Mar. 31, 2017	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Description of Business [Line Items]
Royalty Revenues From Sales Percentage							7.00%	64.00%
Royalty Revenue, Total							$ 8,379,000	$ 8,314,000
Decreases Of Royalty Revenues					$ 150,000
Payment Of Milestone Payments							7,000,000
Other Receivables, Net, Current				$ 3,500,000			3,500,000
Accounts Payable, Current				225,000	213,000		225,000	$ 770,000
Due from Related Parties, Current				111,000			111,000
Merck Co Inc [Member]
Description of Business [Line Items]
Royalty Revenue, Total						$ 7,000,000	7,000,000
Decreases Of Royalty Revenues				$ 111,000	150,000	564,000	877,000
Proceeds from Royalties Received			$ 770,000
Percentage of Equity Interest Sold			25.00%
Nektar Therapeutics Inc [Member]
Description of Business [Line Items]
Proceeds from Royalties Received		$ 3,500,000				$ 3,500,000	$ 3,500,000
PegIntron [Member]
Description of Business [Line Items]
Decreases Of Royalty Revenues					$ 150,000
Subsequent Event [Member] | Merck Co Inc [Member]
Description of Business [Line Items]
Increase (Decrease) in Other Receivables	$ 313,000

Accounts Payable and Accrued 28

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts Payable, Accrued Expenses and Other [Line Items]
Professional and consulting fees	$ 142	$ 140
Other	1	30
Accrued expenses and other	$ 143	$ 170

Accounts Payable and Accrued 29

Accounts Payable and Accrued Expenses (Details Textual) - USD ($)	1 Months Ended	3 Months Ended			12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Accounts Payable, Accrued Expenses and Other [Line Items]
Accrued Royalties							$ 770,000
Royalty Interest Rate					25.00%
Royalty Revenue, Total					$ 8,379,000	$ 8,314,000
Decreases Of Royalty Revenues			$ 150,000
Merck Co Inc [Member]
Accounts Payable, Accrued Expenses and Other [Line Items]
Royalty Withheld					1,600,000	1,600,000
Due to Related Parties		$ 225,000			225,000	$ 770,000
Royalty Revenue, Total				$ 7,000,000	7,000,000
Decreases Of Royalty Revenues		$ 111,000	$ 150,000	$ 564,000	$ 877,000
Merck Co Inc [Member] | Subsequent Event [Member]
Accounts Payable, Accrued Expenses and Other [Line Items]
Increase (Decrease) in Other Receivables	$ 313,000

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - shares	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	3,000,000	3,000,000
Non-Qualified and Incentive Stock Plans [Member]
Class of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	7,097,697
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	100,000

Miscellaneous Income (Details T

Miscellaneous Income (Details Textual)	12 Months Ended
	Dec. 31, 2016USD ($)
Miscellaneous Income [Line Items]
Operating Leases, Income Statement, Sublease Revenue	$ 42,000

Cash Dividend (Details Textual)

Cash Dividend (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 10, 2017	Nov. 14, 2016	Aug. 30, 2017	Dec. 12, 2016	Nov. 28, 2016	Sep. 26, 2016	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Cash Dividend [Line Items]
Common Stock, Dividends, Per Share, Declared	$ 0.15	$ 0.15
Payments of Ordinary Dividends, Common Stock			$ 6,600	$ 6,600	$ 6,600	$ 6,600	$ 6,632	$ 6,632

Income (Loss) Per Common Shar33

Income (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income (Loss) per Common Share - Basic
Net income (loss) for year	$ 5,445	$ (1,126)
Weighted-average number of common shares outstanding	44,215	44,215
Basic income (loss) per share (in dollars per share)	$ 0.12	$ (0.03)
Income (Loss) per Common Share - Diluted
Net income (loss) for year	$ 5,445	$ (1,126)
Weighted-average number of common shares outstanding	44,215	44,215
Weighted-average incremental shares related to assumed exercise of stock options, vesting of nonvested shares, and ESPP	0	0
Weighted-average common shares outstanding and common share equivalents	44,215	44,215
Diluted income (loss) per share (in dollars per share)	$ 0.12	$ (0.03)

Stock Options (Details)

Stock Options (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stock Option [Line Items]
Options, Outstanding at January 1, 2017	219
Options, Granted at exercise prices which equaled the fair value on the date of grant	0
Options, Exercised	0
Options, Expired and forfeited	(177)
Options, Outstanding at December 31, 2017	42	219
Options, Vested and expected to vest at December 31, 2017	42
Options, Exercisable at December 31, 2017	42
Weighted Average Exercise Price per Option, Outstanding at January 1, 2017	$ 2.66
Weighted Average Exercise Price per Option, Granted at exercise prices which equaled the fair value on the date of grant	0
Weighted Average Exercise Price per Option, Exercised	0
Weighted Average Exercise Price per Option, Expired and forfeited	0
Weighted Average Exercise Price per Option, Outstanding at December 31, 2017	3.11	$ 2.66
Weighted Average Exercise Price per Option, Vested and expected to vest at December 31, 2017	3.11
Weighted Average Exercise Price per Option, Exercisable at December 31, 2017	$ 3.11
Weighted Average Remaining Contractual Term (years), Outstanding	3 years 2 months 23 days	2 years 7 months 6 days
Weighted Average Remaining Contractual Term (years), Vested and expected to vest at December 31, 2017	3 years 2 months 23 days
Weighted Average Remaining Contractual Term (years), Exercisable at December 31, 2017	3 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding at January 1, 2017	$ 0
Aggregate Intrinsic Value, Outstanding at December 31, 2017	0	$ 0
Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2017	0
Aggregate Intrinsic Value, Exercisable at December 31, 2017	$ 0

Stock Options (Details Textual)

Stock Options (Details Textual) - USD ($) $ / shares in Units, shares in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Allocated Share-based Compensation Expense	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0	$ 0
Stock or Unit Option Plan Expense	$ 0	$ 0
2011 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	5
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	4.4

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Current:
Federal	$ (1,801)	$ 19
State and foreign	2	2
Total current	(1,799)	21
Deferred:
Deferred: Federal and State	3,362	7,749
Income tax provision (benefit)	$ 1,563	$ 7,770

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Schedule of Income Taxes [Line Items]
Income tax provision at federal statutory rate	$ 2,453	$ 2,325
Add (deduct) effect of:
State income taxes, net of federal tax	970	621
Refundable AMT credit	(1,801)	0
Effect of tax rate change as a result of 2017 Tax Cuts and Jobs Act	16,869	0
Expiration of state tax credits	0	3,303
Expiration of stock options	0	2,144
Permanent difference	0	57
Change in valuation allowance	(14,549)	(680)
Recognition of windfall NOLs	(2,379)	0
Income tax provision (benefit)	$ 1,563	$ 7,770

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Federal and state net operating loss carryforward	$ 24,399	$ 40,359
Research and development credits carryforward	16,608	16,608
Capital loss carryforwards	332	482
Federal alternative minimum tax credits	0	1,801
Total gross deferred tax assets	41,339	59,250
Less valuation allowance	(41,339)	(55,888)
Net deferred tax assets	$ 0	$ 3,362

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate		35.00%
Operating Loss Carryforwards, Limitations on Use		At December 31, 2017, the Company had federal net operating loss carryforwards of approximately $106 million that expire in the years 2022 through 2031 and New Jersey state net operating loss carryforwards of approximately $29 million that expire in the years 2030 through 2031. The Company also has federal capital loss carryforwards of approximately $1.2 million that expire in 2018 and federal research and development tax credit carryforwards of approximately $16.6 million for tax reporting purposes that expire in the years 2018 through 2020. The Companys ability to use the net operating loss and research and development tax credit carryforwards is subject to certain limitations due to ownership changes, as defined by rules pursuant to Section 382 of the Internal Revenue Code of 1986, as amended.
Additional Minimum Tax Credit		$ 140,000
Refund of Tax Credit Description		In addition, the Act repeals the corporate alternative minimum tax (AMT) for years beginning after December 31, 2017 and allows companies with existing alternative minimum tax credit (MTC) carryforwards as of December 31, 2017 to receive refunds of the credits in tax years after 2017 and before 2022 in an amount equal to 50% (100% in 2021) of the excess MTC over the amount of the credit allowable for the year against regular tax liability.
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax		$ 0	$ 1,801,000
Income Taxes Receivable, Noncurrent		1,940,000	$ 0
Increase (Decrease) in Deferred Income Taxes		$ 16,900,000
Scenario, Plan [Member]
Income Taxes [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	21.00%

Significant Agreements (Details

Significant Agreements (Details Textual)	12 Months Ended
	Dec. 31, 2017
Significant Agreements Line item [Line Items]
Percentage Of Royalty Payable Sold Under Merck Agreement	25.00%

Leases (Details Textual)

Leases (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	Mar. 01, 2016	Feb. 04, 2016	Dec. 31, 2017	Dec. 31, 2015	Feb. 28, 2019
Leases [Line Items]
Sub Lease commencement Date			Nov. 14, 2013
Sublease Expiration Date			Jul. 30, 2021
Severance Costs				$ 52,000
Accrued Lease Termination Costs Current				$ 4,506,000
Prime Landlord Mortgage [Member]
Leases [Line Items]
Operating Leases, Rent Expense, Contingent Rentals		$ 4,250,000
Prime Landlord [Member]
Leases [Line Items]
Operating Leases, Rent Expense, Contingent Rentals		$ 204,000
Regus Management Group [Member]
Leases [Line Items]
Payments for Leasing Costs	$ 2,418
Operating Leases, Rent Expense, Minimum Rentals	$ 1,209
Regus Management Group [Member] | Scenario, Forecast [Member]
Leases [Line Items]
Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals					$ 1,259

Other Corporate Events (Details

Other Corporate Events (Details Textual)	May 20, 2016$ / shares
Minimum [Member]
Share Price	$ 1